Navidea Biopharmaceuticals Inc Share Price Nyse
Equities
US63937X1037
Biotechnology & Medical Research
Sales 2021 | 532K 42.55M | Sales 2022 | 65.65K 5.26M | Capitalization | 6.78M 543M |
---|---|---|---|---|---|
Net income 2021 | -11M -881M | Net income 2022 | -15M -1.2B | EV / Sales 2021 | 50.2 x |
Net cash position 2021 | 3.48M 279M | Net Debt 2022 | 440K 35.2M | EV / Sales 2022 | 110 x |
P/E ratio 2021 |
-2.5
x | P/E ratio 2022 |
-0.38
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 64.11% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Dais
DFI | Director of Finance/CFO | 58 | 27/07/23 |
Michael Blue
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/20 |
Richard McFerron
LAW | General Counsel | - | 31/03/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joshua Wilson
BRD | Director/Board Member | 47 | 29/09/22 |
John Scott
BRD | Director/Board Member | 69 | 07/07/21 |
Jill Stefanelli
BRD | Director/Board Member | 46 | 31/05/23 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |